New Drug Delivery System Could Reduce the Dose Needed to Treat Pancreatic Cancer

A Massachusetts General Hospital research study suggests that a nanoparticle drug-delivery system that combines two complementary types of anticancer treatment could improve outcomes for patients with pancreatic cancer and other highly treatment-resistant tumors, while decreasing treatment toxicity. The new system, which combines a light-activated nanoparticle with a molecular therapy drug, reduced the dosage required to suppress tumor progression and metastatic outgrowth by 1,000 percent. Tayyaba Hasan, PhD, of the Wellman Center for Photomedicine is the corresponding author of the study.


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s